Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis

Launched by BEIJING 302 HOSPITAL · Apr 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect high-risk varices, which are swollen veins in the esophagus that can occur in people with liver cirrhosis. The goal is to see if a device called iLivTouch can help identify these dangerous varices more effectively, following guidelines set by the Baveno VI group. Researchers are currently looking for participants aged 18 to 75 who have been diagnosed with liver cirrhosis. To join, participants must have undergone an examination called esophagogastroduodenoscopy within the last three months and not have experienced any serious liver-related complications during that time.

If you or a family member joins the study, you can expect to have your liver health monitored using the iLivTouch device, alongside the traditional endoscopy. It's important to note that certain conditions may exclude potential participants, such as severe liver complications, recent surgeries, or specific medications. This trial aims to improve the way doctors can screen for high-risk varices, which could ultimately help prevent serious health issues for patients with liver cirrhosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-75;
• • 2. Patients with liver cirrhosis diagnosed by clinical or imaging diagnosis;
• • 3. The interval of iLivTouch and esophagogastroduodenoscopy is no more than 3 months;
• Exclusion Criteria:
• • 1. the interval between esophagogastroduodenoscopy and iLivTouch is more than 3 months;
• • 2. any decompensation events (ascites, hepatic encephalopathy or gastroesophageal variceal bleeding) during endoscopy or iLivTouch examination, or during the interval between them;
• • 3. currently taking nonselective beta blocker/ antiplatelet / anticoagulant drugs;
• • 4. hepatocellular carcinoma;
• • 5. after transjugular intrahepatic portosystemic shunt surgery;
• • 6. after liver transplantation.
• • 7. portal-spleen-mesenteric venous thrombosis;
• • 8. patients with splenectomy;
• • 9. BMI ≥ 30;
• • 10. patients with acute active hepatitis or patients with cholestatic hepatitis;
• • 11. IQR/median of liver stiffness measurement \> 30%.